Long Corridor Asset Management LTD Zai Lab LTD Transaction History

Long Corridor Asset Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 30, 2023	BUY	$22.72 - $31.49 $340,800 - $472,350	15,000 Added 93.75%	31,000 $753,000
Q1 2023 May 05, 2023	BUY	$30.21 - $48.1 $483,360 - $769,600	16,000 New	16,000 $532,000
Q1 2022 Apr 25, 2022	SELL	$27.77 - $64.4 $186,059 - $431,480	-6,700 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$54.9 - $105.21 $32,940 - $63,125	600 Added 9.84%	6,700 $421,000
Q3 2021 Nov 12, 2021	SELL	$105.0 - $178.37 $36,750 - $62,429	-350 Reduced 5.43%	6,100 $643,000
Q2 2021 Aug 10, 2021	BUY	$125.11 - $180.0 $806,959 - $1.16 Million	6,450 New	6,450 $1.14 Million

122

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.73B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Long Corridor Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Long Corridor Asset Management LTD with notifications on news.